AB Science
CompanyFranceFounded 2001
AB Science develops one asset, in phase 3 (masitinib in Alzheimer's disease). Mostly small molecule acting on inflammation, CSF1R and PDGFRB; based in France, founded in 2001.
- 1
- Asset
- Furthest
- Phase 3
- 34
- Trials
- 2
- Signals
Pipeline
1Tyrosine kinase inhibitor targeting c-Kit, PDGFR, and Lyn to modulate mast cells and microglia.
Phase 3, Small molecule, Inflammation, CSF1R, Alzheimer's disease, amyotrophic lateral sclerosis
Full company profiles: pipeline, trials, funding and people.
See ProIn the full profile
- Evidence behind the mechanisms5
- Trials34
- Signals3
- Similar companies6
Updated 9 Oct 2026 · 67 sources